Sabrina Paganoni, AAN 2021: Treatment Options for the Management of ALS
It was a pleasure to interview Sabrina Paganoni (Harvard Medical School, Boston, MA, USA) to discuss treatment options for the management of amyotrophic lateral sclerosis (ALS).
The abstract entitled: ‘Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- Could you give us a brief overview of the current status of disease-modifying therapies for ALS? (0:06)
- Why are there so few treatment options for the management of ALS? (1:26)
- What is AMX0035 and what is its mechanism of action? (2:37)
Disclosures: Sabrina Paganoni reports research grants from Amylyx Therapeutics, Revalesio Corporation, Ra Pharma, Biohaven, Clene, Prilenia, The ALS Association, the American Academy of Neurology, ALS Finding a Cure, the Salah Foundation, the Spastic Paraplegia Foundation, the Muscular Dystrophy Association; and reports personal consulting fees for advisory panels from Orion.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Neuromuscular Diseases
Francesco Saccà, EAN 2022: Improving quality of life for patients with generalized myasthenia gravis – ADAPT trial findings
The ADAPT trial (NCT03669588) supported US Food and Drug Administration approval of efgartigimod alfa-fcab in generalized myasthenia gravis. Dr Francesco Saccà (University of Naples Federico II, Naples, Italy) discussed the findings of the study, in terms of health-related quality-of-life outcomes. Questions: 1. What are the current challenges in managing cases of generalized myasthenia gravis? (00:14) […]
James Howard AAN 2022: Ravulizumab for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis – Results from the phase 3 CHAMPION-MG OLE trial
Ravulizumab has recently been approved by in the US for the treatment of adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). Prof. James Howard (The University of North Carolina at Chapel Hill, NC, USA) kindly joins touchNEUROLOGY to discuss the phase 3 CHAMPION-MG trial open label extension study that evaluated the efficacy and […]
James Howard, AAN 2022: Unmet needs in the treatment of myasthenia gravis
Myasthenia gravis (MG) is a rare autoimmune disorder caused by antibodies that act against the myoneural junction, resulting in weakness of the skeletal muscles. Prof. James Howard (The University of North Carolina at Chapel Hill, CA, USA) discusses the unmet needs in the treatment of this rare disease, including, quality of life of patients, response to […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!